ARVN250117P22500
- 5.06
- 0.000.00%
Arvinas Newsroom
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Evercore Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $110
Arvinas Holding Company (ARVN) Receives a Buy From Evercore ISI
Arvinas Analyst Ratings
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $87
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Promising Potential and Strong Efficacy of Arvinas Holding's Vepdeg+Abema Combination Drive Buy Rating
Arvinas Initiated With a Buy at BTIG
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $67
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Arvinas Holding's VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price Target
Arvinas Is Maintained at Outperform by BMO Capital
Arvinas Price Target Cut to $88.00/Share From $90.00 by BMO Capital
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $88